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Abstract
Previous studies in mice with multiple gestational exposures to perfluorooctanoic acid (PFOA)
demonstrate numerous dose dependent growth and developmental effects which appeared to
worsen if offspring exposed in utero nursed from PFOA-exposed dams. To evaluate the
disposition of PFOA in the pregnant and lactating dam and her offspring, time-pregnant CD-1
mice received a single 0, 0.1, 1, or 5 mg PFOA/kg BW dose (n = 25/dose group) by gavage on
gestation day 17. Maternal and pup fluids and tissues were collected over time. Pups exhibited
significantly higher serum PFOA concentrations than their respective dams, and their body burden
increased after birth until at least postnatal day 8, regardless of dose. The distribution of
milk:serum PFOA varied by dose and time, but was typically in excess of 0.20. These data suggest
that milk is a substantial PFOA exposure route in mice and should be considered in risk
assessment modeling designs for this compound.
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Perfluorooctanoic acid (PFOA) is a member of the perfluoroalkyl acid (PFAA) family of
man-made, fluorinated organic compounds used in a number of consumer goods and
industrial surfactants due to their grease and water-repellant properties. The use of PFAAs in
many common applications, such as stain repellants for clothing, carpeting, and upholstery,
and the stability of the carbon–fluorine bond have made them ubiquitous in the environment.
The predominant route of exposure in North American and European consumers is likely
oral intake, including drinking water, while inhalation and dermal absorption comprise
routes of lesser exposure [1–5].
PFAAs are persistent, readily absorbed, not known to be metabolized, and are poorly
eliminated, with half-lives in humans ranging from roughly 4 to 8 years [2–4]. In fact, the
arithmetic and geometric mean half-lives of serum elimination, respectively, were 5.4 years
[95% confidence interval (CI), 3.9–6.9] and 4.8 years (95% CI, 4.0–5.8) for PFOS; 8.5 years
(95% CI, 6.4–10.6) and 7.3 years (95% CI, 5.8–9.2) for PFHS; 3.8 years (95% CI, 3.1–4.4)
and 3.5 years (95% CI, 3.0–4.1) for PFOA [4].
These characteristics led to increased concern for the potential health risks of PFAAs and a
program to reduce product and emission content of PFOA and related chemicals was
recently initiated [1]. PFAAs are continually detected worldwide in both human and wildlife
samples [3,6–9]. A recent analysis of American Red Cross blood donors indicated a
reduction of 60% in blood perfluorooctane sulfonate (PFOS) and 25% in blood PFOA levels
between the years 2000 and 2006 [10]. However, while the production of and potential for
human and wildlife exposures to certain PFAAs has been reduced in the US in recent years,
it is not clear that perfluorinated compounds produced in other countries will not continue to
replace them in the US marketplace or in the contribution to worldwide exposure.
Much of the recent health effects research on PFOA in mice, commonly associated with
gestational exposures of 0.01–5 mg PFOA/kg BW, has focused on developmental toxicities
such as decreased maternal weight gain, reduced neonatal survival and body weight, as well
as later life effects such as pubertal delays, mammary gland abnormalities, and excessive
weight gain [2,11–16]. Early postnatal adverse health observations prompted studies
examining the effect of PFOA on maternal lactation and health effects of the nursing
offspring. White et al. [14] described reduced epithelial differentiation on postnatal day
(PND) 10 in mammary glands of CD-1 mouse dams exposed to 5 mg PFOA/kg BW from
GD1–17, as well as delays in epithelial involution and alterations in milk protein gene
expression on PND20. In addition, female offspring of exposed dams displayed stunted
mammary epithelial branching and growth on PND10 and PND20. In a cross-foster study
utilizing CD-1 mice, Wolf et al. [16] reported that although in utero exposure to 5 mg
PFOA/kg BW from GD1–17 in the absence of lactational exposure was sufficient to induce
postnatal body weight deficits and developmental delays, pup survival from birth to weaning
was affected only in those both in utero and lactationally exposed. Furthermore, recent
studies [15] have shown that unexposed neonates lactation-ally exposed to PFOA quickly
developed mammary gland growth deficits and that control dams nursing in utero-exposed
pups (dams exposed via pup grooming) demonstrated slowed differentiation of their own
mammary glands that was evident in whole mount preparations of the tissue by the 5th day
of lactation. These results support a role for impaired lactational development and possibly a
significant lactational transfer of PFOA in the observation of early growth effects.
The concern for potential prenatal and neonatal exposures in humans has been raised further
by the detection of PFAAs in human breast milk and cord blood and the development-
related outcomes associated with these observations. So et al. [17] indicated a range of 47–
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210 ng/l (0.047–0.21 ng/ml) PFOA in 19 samples of breast milk from Chinese women.
PFOA was detected in only 1 of 12 human milk samples collected from 1996 to 2004 in
Sweden at a concentration of 492 pg/ml (0.492 ng/ml) [18], and a mean of 43.8 pg/ml (0.044
ng/ml) was reported for 45 U.S. breast milk samples collected in 2004 [19]. Two studies
recently determined a negative association between PFOA and growth indices in children
with median cord serum levels of 1.6 ng/ml PFOA in the U.S. [20] and 5.6 ng/ml PFOA in
Denmark [21]. While only one sample was found to contain PFOA in the Karrman et al.
[18] study, these researchers reported a significant milk to serum correlation (r2 = 0.7–0.8, p
< 0.05) for other PFAAs detected. Furthermore, Tao et al. [19] suggested that there may be
preferential partitioning of PFOA to milk compared to other PFAAs and also indicated that
women who were nursing for the first time exhibited 49% higher concentrations of PFOA in
breast milk than women who had nursed previously, although inter-individual variation,
daily milk output and milk protein concentration were not taken into consideration. The only
study that has evaluated the distribution coefficient of PFCs between blood and milk in
animal models was a pharmacokinetic study of placental and lactational transport of PFOA
in rats [22]. Although female rats are known to have a serum PFOA half-life of only a few
hours [23], unlike mice which have a half-life of about 15 days [13], the study [22] indicated
concentrations in rat milk approximately 10 times less than that of maternal plasma and that
the milk concentrations were generally of the same magnitude as the concentrations in pup
plasma.
The increasing amount of research confirming the developmental toxicity of PFAAs in
animal studies, coupled with their detection in human cord blood and milk, supports the
need for examining the disposition of PFAAs during pregnancy/lactation in an appropriate
animal model in order to fully establish the association between prenatal/neonatal exposure
and offspring effects. While other studies have examined the pharmacokinetics of PFAAs in
limited contexts, little data currently exist on the disposition of PFOA in pregnant and
lactating mice or their offspring. We recently developed an analytical method for the
analysis of PFOA in mouse serum, urine, milk, mammary tissue, amniotic fluid, and pups
[24]. Utilizing these methods, we report here data on the distribution of PFOA in various
matrices of pregnant and lactating CD-1 mice, as well as the serum concentration and total
body load of their offspring, following a single exposure of PFOA on GD17. These data will
allow us to reduce the uncertainties in risk assessment for this particular PFAA.
2. Materials and methods
2.1. Chemicals
PFOA (ammonium salt; >98% pure), used in animal exposures, was purchased from Fluka
Chemical (Steinheim, Switzerland). PFOA was completely dissolved by agitation in
deionized tap water, in which PFOA was below the level of detection (LOD—0.5 ng/l for
water), and prepared fresh just prior to use.
2.2. Animals
All animal studies were conducted as approved by the National Health and Environmental
Effects Research Laboratory Institutional Animal Care and Use Committee. Confirmed
timed pregnant female CD-1 mice (n = 100) were purchased from Charles River
Laboratories (Raleigh, NC). Pregnant mice were received at the U.S. EPA's Laboratory
Animal Care Facility on gestation day (GD) 14 (day of sperm-positive designated as GD0).
Upon arrival, mice (approximately 12-week-old) were weighed and randomly distributed
among PFOA treatment groups. They were housed individually in polypropylene cages with
Alpha-dri (Shepherd Specialty Papers, Kalamazoo, MI) bedding and nesting materials. They
were provided pelleted chow (LabDiet 5001, PMI Nutrition International LLC, Brentwood,
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MO) and tap water ad libitum (both contained PFOA at concentrations below the LOD).
Animal facilities were controlled for temperature (20–24 °C) and relative humidity (40–
60%), and kept under a 14:10-h light–dark cycle. Mice (n = 25/dose group) received either
water vehicle or a single dose (0.1, 1.0 or 5.0 mg/kg) of PFOA (in water; 10 μl/g) by oral
gavage on GD17.
2.3. Animal assessments and sample collection
Live dam body weights were recorded on GD17, GD18 (prior to parturition), PND1 (day
after parturition), and PNDs 2, 4, 8, 11, and 18. On GD18, 24 h after the PFOA exposure,
five dams in each dose group were sacrificed and trunk blood, urine, amniotic fluid (fluid
immediately surrounding each fetus), and the 4th and 5th mammary gland were collected.
Liver weight, total number of fetuses (live, dead, or resorbed), and fetal weights were
determined. One entire fetus from each litter was euthanized by decapitation and quick
frozen on dry ice in a 15 ml screw-cap vial. Remaining fetuses were quickly euthanized and
discarded. The dam mammary gland, urine, and amniotic fluid were kept on ice, and then
frozen until assayed. The trunk blood was allowed to clot; serum was collected after
centrifugation and frozen until assayed. All samples were kept frozen at −80 °C.
A similar routine was followed on PND1 (48 h after exposure, n = 5 dams/dose group).
Weights of the dam, pups, dam liver, and the number of live pups in each litter were
recorded. A single pup from each litter was weighed, euthanized, and quick frozen in a
collection vial (including all blood). Blood from all remaining pups in each litter was pooled
into a single vial, allowed to clot, and separated to serum by centrifugation. Dam and pup
serum, dam urine and mammary tissue were frozen until assayed. All remaining litters, in all
dose groups, were equalized to 10 pups each on PND1. Biological samples, including a
single pup and pup serum, as described for PND1, were also collected on PNDs 4, 8 and 18
(n = 5 dams/dose group), at the same time of day.
Milk collection was attempted, following administration of oxytocin (1 U/ml, i.p., 20 min
prior to milking) on both GD18 and PND1, but was unsuccessful. Milk was collected on
PNDs 2, 8, 11, and 18 following a 2 h separation of the pups from the dam and an oxytocin
stimulus. The milk was vacuum aspirated using low, pulsatile pressure, into a pre-weighed
microcentrifuge tube. Collected milk was weighed and frozen until analyzed. Biological
samples including urine, dam and pup serum, amniotic fluid, mammary tissue, whole pup,
and milk were analyzed for PFOA using the methods described briefly below and in our
companion paper [24].
2.4. PFOA sample analyses
Briefly, the analysis of PFOA was performed using a Waters Acquity™ ultra-performance
liquid chromatography system interfaced with a Waters Quattro Premier XE triple
quadrupole mass spectrometer (UPLC–MS/MS) (Waters, Milford, MA). Either 25 or 50 μl
of serum and amniotic fluid (50 μl used for controls), 20 μl aliquots of urine and milk, and
300 μl of pup or mammary tissue homogenates were utilized as starting material for these
analyses. Samples were extracted, purified, and concentrated or diluted exactly as described
by Reiner et al. [24]. Ten to forty microliters of the prepared sample, depending on the
concentration of the original exposure, was injected and run on the UPLC–MS/MS [24].
Refer to Reiner et al. [24] for method performance and quality control steps that were
performed to insure the precision and accuracy of the methods used. The limit of
quantitation (LOQ) for these experiments was 5 ng/ml (serum), 1 ng/ml (amniotic fluid,
urine, milk), and 1 ng/g (whole pups, mammary tissue).
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2.5. Urinary creatinine measures
Creatinine concentrations were measured as a basis to evaluate PFOA in mouse urine. The
QuantiChrom creatinine assay (BioAssay Systems, Hayward, CA) exhibited an LOD of 0.10
ng/ml and was linear up to 300 ng/ml. Thirty microliters of each urine sample was prepared
and evaluated at 510 nm singly or in duplicates (five duplicates per set of 20 samples)
according to the manufacturer's instructions. The inter-assay coefficient of variation (CV)
ranged from 4.0 to 6.8% and the intra-assay CV ranged from 0.3 to 16.1%, with an average
of 4.9%. The assay standard accuracy ranged from 0.2 to 8.4%. Urinary PFOA is reported as
corrected for creatinine concentrations (ng PFOA/g creatinine).
2.6. Computations and statistics
Reported PFOA concentrations have been adjusted for dilution or concentration factors, as
well as creatinine levels (ng/g; urine), or the weight of the tissue evaluated (ng/g; mammary
tissue and whole pups). Serum, amniotic fluid, milk and urinary concentrations are reported
as ng/ml. Averages, proportions, and statistical comparisons were calculated with SAS 9.1
(SAS Institute; Cary, NC). Statistical significance was determined using a Proc GLM
ANOVA, with a Dunnett's post hoc comparison, and significance was set at p < 0.05.
3. Results
3.1. Biological outcomes
This is the first study to report single dose disposition of PFOA in pregnant and lactating
mice and their offspring. The doses chosen were based on previous reports in CD-1 mice
[3,14,16] demonstrating developmental health outcomes following multiple gestational
PFOA exposures. A single PFOA exposure on GD17 did not affect the number of live
fetuses (on GD18), implantation sites, or live-born pups (on PND1), or dam body weights
(data not shown). Unlike studies using multiple gestational PFOA exposures [13,25], there
was no change in pup body weight, dam liver weight, and dam liver:BW ratios, within the
PFOA dose range administered in this study (Fig. 1). The rise in dam liver:BW ratio
between GD18 and PND1, which persisted until weaning, was due to the dramatic decrease
in body weight at parturition, as this single late gestation PFOA exposure failed to change
mean liver weight in exposed dams, compared to control values, at any time evaluated.
3.2. PFOA concentrations prior to birth
The mean concentration of PFOA in the amniotic fluid and serum of the exposed dams 24 h
after exposure is shown (Fig. 2; amniotic fluid controls average 3.8 ng/ml). The average
concentration of PFOA detected in dam serum was about twice the amniotic fluid
concentration at each dose evaluated (amniotic fluid was 68.8, 51.8, and 40% of dam serum
levels at 0.1, 1, and 5 mg PFOA/kg BW, respectively). A comparison of the amount of
PFOA in an entire GD18 fetus (body burden/pup ± standard error of the mean [SEM]; Fig.
5) to the GD18 PFOA concentration in amniotic fluid (ng/ml; assuming 1 ml total volume)
reveals 2.3-, 3.1-, and 2.7-fold increased PFOA in the pup vs. the fluid in which it was
contained in utero for 0.1, 1, and 5 mg/kg dose groups, respectively.
3.3. PFOA concentrations in the dams
The serum and urine PFOA concentrations were evaluated in dams that were nursing litters
of approximately 10 pups (PND1 equalized; minimal pup loss over time). As expected, dam
sera contained the highest PFOA concentrations of any matrix evaluated, regardless of dose
(Fig. 3; all serum controls < LOQ). The rise in circulating serum PFOA with increasing dam
exposures was proportional to the change in dose delivered, regardless of stage of lactation
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(i.e., mean 9.9-fold and 5.1-fold increases between 0.1 to 1.0 mg/kg and 1.0 to 5.0 mg/kg
exposures, respectively).
A one-time PFOA exposure of 0.1 mg/kg produced an average dam serum PFOA
concentration (Fig. 3A) of 144–226 ng/ml at 24 and 48 h after exposure, respectively, which
was reduced to an average of 44 ng/ml near the peak of lactation (PND8), and had risen to a
mean of 123 ng/ml by PND18, a time when the pups’ primary caloric intake came from
rodent chow and not milk. The U-shaped serum concentration curve observed in the 0.1 mg
PFOA/kg dose group was also present in the 1 and 5 mg/kg exposure groups.
As shown in Fig. 3 (A–C; control urine and mammary gland PFOA < LOQ), although the
concentrations of PFOA cannot be compared directly between serum, urine, and mammary
tissue, due to the difference in units, it was evident that much less PFOA was being excreted
in dam urine than was present in dam serum, and that mammary tissue contained a
considerable amount of PFOA. While a U-shaped response in dam excretion of PFOA
(urine) was not as pronounced as that of serum, mammary tissue demonstrated a strong U-
shaped response, with the lowest concentrations measured near the peak of lactation, and a
significant rise in concentration apparent again at PND18 (p < 0.05).
When aspirated milk PFOA values were evaluated (Fig. 3D; 1 control > LOQ), a U-shaped
curve over time was again evident. As depicted in Table 1, the percentage of PFOA in milk
(compared to serum) was substantial. Comparing the milk concentrations to the closest
matched dam serum concentrations (by time), the amount of PFOA in the milk consistently
ranged from 1/10 to 1/2 that of dam serum PFOA across dose and time. It appeared that the
day of lactation on which milk PFOA was measured had an important influence on this
relationship. The milk:serum PFOA ratio was greatest in early and late lactation (PND2 and
PND18), ranging from 15 to 56% (means of 33% early and 26% late), while near the peak of
lactation (PND8 and 11), the PFOA milk:serum ratio ranged from 11 to 27% (mean 17.7%).
It was not possible to accurately measure the volume of milk obtained at aspiration, but
precise weights were compared. On PNDs 2, 8, 11, and 18, the average weight of milk
obtained via aspiration of control mice was 0.072, 0.1906, 0.2547, and 0.0457 g,
respectively, demonstrating over a 3.5-fold increase in weight from PND2 to 11 and a 5.6-
fold drop from PND11 to 18.
3.4. PFOA concentrations in the pups
Pup serum PFOA concentration was evaluated on PNDs 1, 4, 8, and 18. In comparing the
average PFOA concentrations in PND1 pups vs. their respective dams (Fig. 4A; whole
control pups and control serum < LOQ), it appeared that circulating pup serum PFOA
concentrations were significantly higher than those measured in dams, regardless of dose (p
< 0.05). Although pups possessed a substantially higher serum PFOA concentration than
dams, the difference in pup and dam blood volumes at those stages of pup development are
considerable. Regardless of those differences, heightened circulating PFOA in pup sera
reflected increased exposures, proportional to dose throughout lactation (i.e., mean 10.4-fold
and 4.3-fold increases between 0.1 to 1.0 mg/kg and 1.0 to 5.0 mg/kg exposures,
respectively).
Unlike their dams, pups did not demonstrate U-shaped serum PFOA concentration curves
(Fig. 4B). Pup serum PFOA concentrations continued to exceed the average dam serum
PFOA concentrations over time, until PND18 when the pup and dam concentrations
approached 1:1. When the PFOA concentration (ng/g) was evaluated in whole pups (pup
and blood; Fig. 5 left panels), a decline in PFOA concentration was detected over time,
across all doses. However, when the rapidly increasing body weight of the pups was taken
into consideration to calculate the total amount of PFOA in the neonate (as shown in Fig. 1),
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a completely different trend was noted (Fig. 5 right panels). Regardless of exposure dose,
PFOA body burden (adjusted for weight) rose through the peak of lactation and had begun
to decline by PND18, demonstrating an inverse U-shaped curve. When the administered
PFOA dose and measured body burden in whole pups (body weight taken into effect) were
compared, the administered PFOA:measured PFOA ratio was no longer proportional
throughout lactation, and were unlike the ratios reported for dam and pup serum PFOA.
Mean body burden ratios of 13.2-fold (range 11.1–17.8) and 4.3-fold (range 3.2–5.1)
increases between 0.1 to 1.0 mg/kg and 1.0 to 5.0 mg/kg exposures, respectively, were
determined.
4. Discussion
These data confirm that on a concentration-based comparison, gestationally PFOA-exposed
pups exhibited a significantly larger serum PFOA load than their dam. That substantial
serum PFOA load in pups was evident 24 h after a single exposure, and was apparently due
to blood-borne (transplacental) transfer. Another important discovery is the U-shaped PFOA
concentration over time, regardless of dose, in the dam mammary tissue, milk, and serum.
This unique PFOA response was not detected in pups or pup serum, and was evident to a
lesser extent in the dams’ urinary excretion curves. However, when PFOA body burden in
whole pups was the unit of measure, an inverse U-shaped curve was apparent, and the PFOA
burden of pups is proposed to increase due to milk-borne PFOA intake.
The decline in concentration seen in the milk, mammary and serum U-shaped curves is
hypothesized to be due to hydro-dilution associated with increased blood and milk volumes.
Several physiological conditions are changed during lactation that have been well
documented in rats and directly relate to mice, as their lactation period is of the same length.
A decrease in total plasma proteins due to increased blood volume, cardiac output, and
blood flow to certain tissues, such as the mammary gland, has been reported in rats [26,27].
Elevated blood volume is due to increased plasma volume [27]. Milk yield (g/h) in rats was
reported to reach its peak by PND10 [27] and the rat mammary gland reaches its maximum
size (as % body weight) by PND15 [26], with a steep rise in size from PND5–15. Rat
mammary gland blood flow and volume of milk produced are directly related, when
measured on PND15 [26]. Total serum proteins are lower in lactating rats that those
measured in non-lactating rats [27], and in humans, serum albumin concentration decreases
during pregnancy and early lactation [28]. Further, at 14 days postpartum, the cardiac output
of lactating rabbits was 30% higher than that in non-lactating animals, and the mammary
gland was the only organ shown to increase in weight, relative to body weight [29].
Although a complete set of data that could address the exact reason for the U-shaped curves
during lactation was not collected in this study, the aspirated milk weights did reveal a
dramatic increase in milk volume (assumed due to weight change) from PND2 up to the
peak of lactation (PND11). This dramatic change in volume (weight) may explain the
decrease in milk PFOA concentration seen between PND2 and PND11. PFOA also appears
to concentrate in serum and milk near the end of lactation (PND18, for example) when pups
are eating more chow and suckle less often. Mammary gland blood flow has been reported
to decrease by half in a 24 h period, after suckling rat offspring are removed from their dam
[26], and this fall in mammary blood flow is directly associated with decreased cardiac
output and % blood flow used by the mammary gland. In this study a precipitous drop in
weight of milk collected between the peak of lactation and PND18 was noted, indicating a
rapid decrease in milk volume. Therefore, the U-shape of the dam PFOA curves are
proposed to be driven by physiological dilution and concentration of the PFOA load over the
period of lactation, reaching the greatest dilution at or near the peak of lactation when the
milk volume produced by the dam and consumed by the pups is the greatest. Increased
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consumption of milk up to PND11 likely directly contributed to the accumulation of body
burden in the pup over this life stage.
A significant contribution of milk-borne PFOA transfer in CD-1 mice was detected in these
studies. Previous reports in rats [22] and humans [18] have estimated that the dam PFOA
milk:serum distribution ratio was 0.1 and 0.01, respectively. In the present study, the
distribution ratio ranged from slightly more than 0.1 to over 0.5 in mice, depending on dose,
with the lowest doses tested demonstrating the highest ratios over time. If the milk PFOA
concentrations had been measured near the peak of lactation only (PND 8–11), the 0.1
milk:sera distribution estimate previously reported for rats in midlactation [22] may have
also been presumed true in mice. However, at two periods during lactation (early and late)
spikes of increased milk:serum ratios appeared, regardless of dose, with a substantial peak in
milk PFOA concentrations on PND2. Although volumes of milk large enough to perform
analytical measures prior to PND2 were not able to be obtained, we suspect, based on the
significant PFOA concentrations in the PND1 mammary gland, that substantial milk PFOA
concentrations would have been evident on PND1, as well, primarily due to being
condensed in small milk volumes.
In previous reports by Lau et al. [13], Wolf et al. [16], and White et al. [14], decreased body
weight gain and neonatal mortality were evident on several days just after birth in CD-1
mouse litters gestationally exposed to 3 mg/kg PFOA and higher. In fact, in a cross-foster
study [16] demonstrating decreased body weight gain at 5 mg/kg from in utero exposure
only, significant decreases in body weight gain were detected in the 3 mg/kg dose group
only when in utero-exposed mice were also allowed to nurse from a PFOA exposed dam.
Even at 5 mg/kg, there was no evidence of decreased pup body weight or neonatal mortality
in the current study, following a single gestational PFOA exposure. Our PFOA
measurements in whole pups indicate that the PFOA body burden accumulates in early life,
and starts to decline as pups mature, open their eyes, and begin to eat chow and drink water.
Our data and those demonstrating deleterious health outcomes suggest that the milk of
gestationally PFOA-exposed mice was a major source of continued exposure to this
compound for the developing pups.
As expected, large differences in dam and pup serum PFOA concentrations from those
previously reported [14,16] were noted, and those differences bring to light the issue of
single vs. multiple dose kinetics. As noted for PFOS, single dose kinetics may differ
substantially from those involving repeated doses [30]. Concentration dependent changes in
clearance can result in discrepancies between single and repeated dose kinetics.
A limited number of epidemiological studies have revealed associations between health
outcomes (birth weight, head circumference) and cord blood or maternal serum PFOA
concentrations in humans [20,21], while other studies failed to detect associations with later
developmental milestones in infants [31]. Several studies have now measured PFAAs in
human milk [17–19,32,33], however, only one study has been able to approximate the
milk:serum relationship of PFOA transfer [18]. The reported 0.01 (1/100th) relationship was
determined from a single voluntarily contributed sample at 3 weeks postpartum. According
to the mouse milk:serum PFOA distribution over time that we report herein, the values
reported in one human [18] and rats [22] may not be representative of the PFOA distribution
to milk throughout lactation in those species.
In conclusion, these studies confirmed and further defined considerable PFOA exposures to
mouse offspring following a single gestational exposure. They also demonstrated the
accumulation of chemical over time in whole pups, which likely results from milk-borne
PFOA, an exposure that had previously been incompletely assessed in other species. A
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single 0.1 mg/kg PFOA exposure to a pregnant mouse induced circulating serum PFOA
concentrations of 44–216 ng/ml in dams and 117–326 ng/ml in pups; values comparable to
serum PFOA concentrations of children that were accidentally exposed via DuPont
production plant emission [34]. Because of evidence [15,35] demonstrating neonatal and
latent health effects following developmental exposures to PFOA in mice, associated with
higher circulating PFOA levels than those reported here, continued studies evaluating
exposure–effect relationships are warranted in children.
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GD gestational day
LOD limit of detection






SEM standard error of the mean
UPLC ultra-performance liquid chromatography
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Dam tissue weights and average pup weights following a single gavage PFOA exposure on
GD17. PFOA was without effect on several biological end points (p > 0.05), such as dam
body weight measured on several postnatal days (PND) and on gestation day (GD)18 (not
shown). (A) Dam liver weight, (B) liver:body weight ratio, and (C) pup body weight over
time or numbers of live pups or fetuses (not shown) were also unchanged by a single PFOA
exposure. Data are shown as mean ± SEM or as a mean ratio.
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Comparison of gestation day (GD)18 dam serum and amniotic fluid PFOA concentrations.
PFOA concentrations were significantly higher in dam serum than amniotic fluid at all doses
evaluated (p < 0.05). Data are shown as mean ± SEM.
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PFOA concentrations in exposed dams. PFOA concentrations were measured in dam serum
(A; ng/ml), urine (B; ng/g creatinine), and mammary tissue (C; ng/g tissue weight) on
postnatal days (PND) 1, 4, 8 and 18. PFOA concentrations were measured in aspirated milk
samples collected on PNDs 2, 8, 11, and 18 (D; ng/ml). Although panels A and C and B and
D cannot be directly compared (due to different units), the U-shaped concentration curve
present in dam serum (regardless of dose) was also detected in mammary tissue and
aspirated milk. Data are shown as mean ± SEM. †Denotes a single reliable measurement at
this time due to insufficient volumes in other dams at this dose and time.
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Neonatal transfer of PFOA to pups. (A) A significantly higher PFOA concentration in pup
vs. dam serum on PND1 was noted (p < 0.05; v:v). (B) Pooled pup serum PFOA
concentrations did not demonstrate a U-shaped curve, but gradually declined over time,
presumably due to dilution of dose by increased growth-related blood volume. Data are
shown as mean ± SEM.
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Whole pup PFOA concentrations. PFOA concentrations were measured in a representative
whole pup (pup and blood; ng/g; left panels) from each litter. Although there is a consistent
downward trend in PFOA concentration over time, the rapidly increasing blood volume and
body weight changes must be taken into consideration when interpreting these data. Body
weight-adjusted values (right panels; [ng/g PFOA measures × g body weight = body
burden]) demonstrate an accumulation of exposure until late in the lactational period. Data
are shown as mean ± SEM.
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